Pharmena SA, a biotechnology company listed on the Warsaw Stock Exchange’s main market, reported PLN 1.2 million in cumulative sales after the first three quarters of 2025. This represents more than a sixfold increase compared with the same period last year (PLN 180,000). The operating loss for the nine-month period amounted to PLN 2.3 million, slightly lower than in the corresponding period of 2024 (PLN 2.5 million). Despite higher selling costs, the reduction in losses was primarily driven by a significant decrease in general and administrative expenses. During the reporting period, Pharmena focused on expanding the distribution network for its 1-MNA-based Endotelio line of dietary supplements. Meanwhile, its medical device for hard-to-heal wounds is awaiting the launch of key development stages ahead of commercialization.
“After three quarters, sales revenues were over PLN 1 million higher than a year earlier, which is a very positive signal for us. At the same time, we continue to look for new distribution channels to build sales and accelerate growth. We are also noticing increasing interest from international customers, which gives us additional motivation to keep developing,” said Konrad Palka, CEO of Pharmena SA.
In the first three quarters of 2025, the company concentrated on activities aimed at building awareness of the 1-MNA molecule and the Endotelio brand among opinion leaders, while simultaneously developing its presence in European and North American markets. Pharmena’s products based on the 1-MNA molecule help maintain optimal NAD+ levels—an essential coenzyme that supports metabolism, cellular regeneration and the deceleration of aging processes, which intensify after the age of 30. The company also continued work on developing new dietary supplement formulations.
The project involving a medical device designed for hard-to-heal wounds is now entering a decisive phase, with clinical testing among the key steps still ahead. At the end of 2023, Pharmena announced that it had begun preparations for market implementation, having already completed several milestones. These include the conceptual design and development of an initial formula. In September this year, the company signed an agreement with a specialized firm to prepare a Biological Evaluation Plan, conduct biocompatibility assessments and compile a Biological Evaluation Report for the future medical device. The upcoming clinical trial remains the project’s next major milestone.
According to 2022 data, the global market for products supporting the treatment of hard-to-heal wounds exceeded USD 20 billion, with nearly 20% attributed to at-home treatment solutions. The market is expected to grow at an annual rate of approximately 5.5% over the next decade.
Source: CEO.com.pl — Pharmena with sixfold increase in sales; company accelerates despite losses
